The overall objective of Core A is to provide analytical support to Projects 1, 2, and 3 and the Probe and Pharmaceutical Optimization Core (Core B). Core A is an integral part of the center by providing advanced analytical support, training, and cutting edge analytical techniques for drug and biomarker detection. More specifically, Core A will develop methods for the detection of target compounds and their metabolites by LC-MS or GC-MS and provide QC analysis of standard solutions prior to their use in projects. Detailed rodent ADME studies for the anticonvulsants and neuroprotectants will be performed to assist the center projects in dose selection. Core A will work with Project 2 in the identification of biomarkers of seizure as a biochemical test of how therapeutic efficacy. Metabolomics techniques, both targeted and global will be employed. Targeted metabolomics will focus on both oxylipins and neurosteroids since levels in both pathways are altered after a seizure. Global metabolomics, as a broader approach, can identify biomarkers of seizure and therapy if needed. Current methods of detection of tetramethylenedisulfotetramine (TETs) are insensitive. TETs seems like an ideal candidate for an immunoassay, since it has several heteroatoms to provide recognition points for the antibody. An additional benefit of immunoassay is its potential to be packaged in a field deployable platform for on-site detection. When there is a clear need, immunoassays to other toxins and their metabolites will be created. Objective-1: Provide general analytical support using GC-MS or LC-MS for the detection of toxins or drugs and their metabolites in biological matrices and formulations. Objective-2: Determine the metabolomic profiles of brain tissue from Projects 1 and 2 as biomarkers of seizure damage for use in assessing neuroprotective efficacy of candidate therapeutics. Objective-3: Develop innovative immunoassay methods for detection of TETs in biological and environmental matrices.

Agency
National Institute of Health (NIH)
Institute
National Institute of Neurological Disorders and Stroke (NINDS)
Type
Specialized Center--Cooperative Agreements (U54)
Project #
5U54NS079202-03
Application #
8730734
Study Section
Special Emphasis Panel (ZRG1-MDCN-J)
Project Start
Project End
Budget Start
2014-09-01
Budget End
2015-08-31
Support Year
3
Fiscal Year
2014
Total Cost
$402,708
Indirect Cost
$141,209
Name
University of California Davis
Department
Type
DUNS #
047120084
City
Davis
State
CA
Country
United States
Zip Code
95618
Tu, Ranran; Armstrong, Jillian; Lee, Kin Sing Stephen et al. (2018) Soluble epoxide hydrolase inhibition decreases reperfusion injury after focal cerebral ischemia. Sci Rep 8:5279
Hampe, Alexander E; Li, Zidong; Sethi, Sunjay et al. (2018) A Microfluidic Platform to Study Astrocyte Adhesion on Nanoporous Gold Thin Films. Nanomaterials (Basel) 8:
Hobson, Brad A; Rowland, Douglas J; Supasai, Suangsuda et al. (2018) A magnetic resonance imaging study of early brain injury in a rat model of acute DFP intoxication. Neurotoxicology 66:170-178
Moeller, Benjamin; Espelien, Brenna; Weber, Waylon et al. (2018) The pharmacokinetics of ketamine following intramuscular injection to F344 rats. Drug Test Anal :
Pressly, Brandon; Nguyen, Hai M; Wulff, Heike (2018) GABAA receptor subtype selectivity of the proconvulsant rodenticide TETS. Arch Toxicol 92:833-844
Dhir, Ashish; Rogawski, Michael A (2018) Determination of minimal steady-state plasma level of diazepam causing seizure threshold elevation in rats. Epilepsia 59:935-944
Kodani, Sean D; Barthélemy, Morgane; Kamita, Shizuo G et al. (2017) Development of amide-based fluorescent probes for selective measurement of carboxylesterase 1 activity in tissue extracts. Anal Biochem 539:81-89
Barnych, Bogdan; Rand, Amy A; Cajka, Tomas et al. (2017) Synthesis of cyclooxygenase metabolites of 8,9-epoxyeicosatrienoic acid (EET): 11- and 15-hydroxy 8,9-EETs. Org Biomol Chem 15:4308-4313
Vasylieva, Natalia; Barnych, Bogdan; Wan, Debin et al. (2017) Hydroxy-fipronil is a new urinary biomarker of exposure to fipronil. Environ Int 103:91-98
Wagner, Karen M; McReynolds, Cindy B; Schmidt, William K et al. (2017) Soluble epoxide hydrolase as a therapeutic target for pain, inflammatory and neurodegenerative diseases. Pharmacol Ther 180:62-76

Showing the most recent 10 out of 85 publications